Follicular Lymphoma - Pipeline Review, H2 2015 Is Released Follicular Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Follicular Lymphoma - Pipeline Review, H2 2015, provides an overview of the Follicular Lymphoma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects - A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most 1
attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179106/follicular-lymphoma-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179106/follicular-lymphoma-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 11 Global Markets Direct Report Coverage 11 Diffuse Large B-Cell Lymphoma Overview 12 Therapeutics Development 13 Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 13 Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 14 Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 15 Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 22 Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Diffuse Large B-Cell Lymphoma - Products under Development by Companies 26 Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 34 Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 35
2
AbbVie Inc. 35 Acetylon Pharmaceuticals, Inc. 36 Affimed Therapeutics AG 37 Amgen Inc. 38 Aprogen, Inc. 39 Arrien Pharmaceuticals, LLC 40 Astellas Pharma Inc. 41 AstraZeneca Plc 42 Aurigene Discovery Technologies Limited 43 Bayer AG 44 BeiGene(Beijing) Co.,Ltd 45 BIND Therapeutics, Inc. 46 Biocon Limited 47 Bristol-Myers Squibb Company 48 Celgene Corporation 49 Cell>Point, L.L.C. 50 Cellular Biomedicine Group, Inc. 51 Constellation Pharmaceuticals, Inc. 52 CTI BioPharma Corp. 53 Curis, Inc. 54 Cyclacel Pharmaceuticals, Inc. 55 Eisai Co., Ltd. 56 EpiZyme, Inc. 57 Erytech Pharma SA 58 3
F. Hoffmann-La Roche Ltd. 59 Genentech, Inc. 60 Gilead Sciences, Inc. 61 GlaxoSmithKline Plc 62 Hutchison MediPharma Limited 63 Idera Pharmaceuticals, Inc. 64 ImmunoGen, Inc. 65 Immunomedics, Inc. 66 Immunovaccine, Inc. 67 Incyte Corporation 68 Inflection Biosciences Limited 69 Johnson & Johnson 70 Juno Therapeutics Inc. 71 Karus Therapeutics Limited 72 Karyopharm Therapeutics, Inc. 73 Kite Pharma, Inc. 74 Mabion SA 75 mAbxience S.A. 76 MedImmune, LLC 77 Medivation, Inc. 78 Merck & Co., Inc. 79 Millennium Pharmaceuticals, Inc. 80 Mirati Therapeutics Inc. 81 4
Mirna Therapeutics, Inc. 82 Molplex Ltd. 83 MorphoSys AG 84 Neumedicines Inc. 85 Nimbus Therapeutics, LLC 86 Nordic Nanovector ASA 87 Novartis AG 88 Ono Pharmaceutical Co., Ltd. 89 Onyx Pharmaceuticals, Inc. 90 Pfizer Inc. 91 Philogen S.p.A. 92 Portola Pharmaceuticals, Inc. 93 ProNAi Therapeutics, Inc. 94 RedHill Biopharma Ltd. 95 Redx Pharma Plc 96 Respiratorius AB 97 Rhizen Pharmaceuticals S.A. 98 Sandoz International GmbH 99 Seattle Genetics, Inc. 100 Selvita SA 101 Taiho Pharmaceutical Co., Ltd. 102 TG Therapeutics, Inc. 103 Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 104 Assessment by Monotherapy Products 104 5
Assessment by Combination Products 105 Assessment by Target 106 Assessment by Mechanism of Action 111 Assessment by Route of Administration 115 Assessment by Molecule Type 117 Drug Profiles 119 187Re-EC-G - Drug Profile 119 ABC-294640 - Drug Profile 120 acalabrutinib - Drug Profile 123 acalisib - Drug Profile 126 ACY-775 - Drug Profile 127 AFM-11 - Drug Profile 129 AFM-13 - Drug Profile 130 alisertib - Drug Profile 131 ARN-3236 - Drug Profile 135 ARN-3261 - Drug Profile 136 ASN-002 - Drug Profile 137 asparaginase - Drug Profile 138 atezolizumab - Drug Profile 140 azacitidine - Drug Profile 144 AZD-2811 - Drug Profile 148 AZD-3965 - Drug Profile 149 AZD-9150 - Drug Profile 151 6
bendamustine hydrochloride - Drug Profile 152 Betalutin - Drug Profile 155 BGB-3111 - Drug Profile 157 blinatumomab - Drug Profile 158 BLyS-gel - Drug Profile 161 BMS-986016 - Drug Profile 162 bortezomib - Drug Profile 163 brentuximab vedotin - Drug Profile 169 buparlisib hydrochloride - Drug Profile 176 BVX-20 - Drug Profile 180 carfilzomib - Drug Profile 181 CBM-C19.1 - Drug Profile 185 CBM-C20.1 - Drug Profile 186 CC-122 - Drug Profile 188 CC-223 - Drug Profile 190 Cellular Immunotherapy for Oncology - Drug Profile 191 Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 192 cerdulatinib - Drug Profile 193 coltuximab ravtansine - Drug Profile 195 copanlisib hydrochloride - Drug Profile 197 CPI-0610 - Drug Profile 201 CPI-169 - Drug Profile 202 CUDC-907 - Drug Profile 203 CYC-065 - Drug Profile 205 7
daratumumab - Drug Profile 206 Darleukin - Drug Profile 210 denintuzumab mafodotin - Drug Profile 212 DPX-Survivac - Drug Profile 213 E-7449 - Drug Profile 217 entospletinib - Drug Profile 218 epacadostat - Drug Profile 219 everolimus - Drug Profile 221 GS-5829 - Drug Profile 227 GSK-2816126 - Drug Profile 228 HMPL-523 - Drug Profile 229 IBL-301 - Drug Profile 230 ibrutinib - Drug Profile 232 idelalisib - Drug Profile 239 IGN-002 - Drug Profile 242 imexon - Drug Profile 243 IMGN-529 - Drug Profile 245 IMO-8400 - Drug Profile 247 inebilizumab - Drug Profile 249 inebilizumab + rituximab - Drug Profile 251 inotuzumab ozogamicin - Drug Profile 252 IT-901 - Drug Profile 254 ixazomib citrate - Drug Profile 255 8
JCAR-014 - Drug Profile 259 JNJ-64052781 - Drug Profile 260 KA-2237 - Drug Profile 261 KTEC-19 - Drug Profile 262 lenalidomide - Drug Profile 265 mitoxantrone hydrochloride - Drug Profile 270 MK-2206 - Drug Profile 271 MK-8628 - Drug Profile 274 mocetinostat - Drug Profile 276 Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers - Drug Profile 279 Monoclonal Antibody to Agonize CD40 for Diffuse Large B-Cell Lymphoma and Solid Tumors - Drug Profile 280 MOR-208 - Drug Profile 281 MRX-34 - Drug Profile 283 NBD Peptide - Drug Profile 285 ND-2110 - Drug Profile 287 ND-2158 - Drug Profile 289 nivolumab - Drug Profile 291 NMIL-121 - Drug Profile 299 obinutuzumab - Drug Profile 301 ONC-201 - Drug Profile 304 pecazine - Drug Profile 307 pembrolizumab - Drug Profile 308 pidilizumab - Drug Profile 317 9
pixantrone dimaleate - Drug Profile 319 PNT-2258 - Drug Profile 323 polatuzumab vedotin - Drug Profile 325 PRT-060318 - Drug Profile 327 Pt-EC-G - Drug Profile 328 rituximab biosimilar - Drug Profile 329 rituximab biosimilar - Drug Profile 330 rituximab biosimilar - Drug Profile 331 rituximab biosimilar - Drug Profile 333 rituximab biosimilar - Drug Profile 334 romidepsin - Drug Profile 335 RP-6530 - Drug Profile 338 ruxolitinib phosphate - Drug Profile 339 SEL-24B489 - Drug Profile 344 selinexor - Drug Profile 345 SGN-CD70A - Drug Profile 351 SH-7129 - Drug Profile 352 Read More http://www.idatainsights.com/reports-landing-page.php?id=179106/follicular-lymphomapipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
10
ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
11